Latest Breaking News On - Babraham research campus in cambridge - Page 1 : comparemela.com

Silverstein appointed Chief Financial Officer at Artios Pharma

Silverstein appointed Chief Financial Officer at Artios Pharma
businessweekly.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessweekly.co.uk Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesNew yorkEmendo biotherapeuticsArtios pharmaNiall martinMerck kgaaCrick instituteNetherlands cancer instituteMerck kgaExcision biotherapeutics incCancer research united kingdomBabraham research campus in cambridgeInstitute of cancer researchRelmada therapeutics incAnges inc

Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer

Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesUnited kingdomCity ofTimothy yapAbid ansariNiall martinLifesci advisorsligia vela reidNature communicationsSarah cannon research institute at tennessee oncologyArtios pharma limitedMerck kgaCrick instituteNetherlands cancer instituteBabraham research campus in cambridgeCancer research technology

Artios initiates Phase 2 study of Pol Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer

Arix Bioscience PLC (ARIX) Artios initiates Phase 2 study of Pol Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BR.

New yorkUnited statesUnited kingdomCity ofIbrahim khalilTimothy yapSarah macleodArix bioscienceArtios pharmaNiall martinNature communicationsSarah cannon research institute at tennessee oncologyArtios pressArtios pharma limitedMerck kgaCrick institute

Investegate |Arix Bioscience PLC Announcements | Arix Bioscience PLC: Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer

Investegate announcements from Arix Bioscience PLC, Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer

New yorkUnited statesUnited kingdomCity ofIbrahim khalilTimothy yapSarah macleodArix bioscienceArtios pharmaNiall martinNature communicationsSarah cannon research institute at tennessee oncologyArtios pressArtios pharma limitedMerck kgaCrick institute

Arix Bioscience PLC: Artios initiates Phase 2 study of Pol? Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer

DJ Artios initiates Phase 2 study of Pol? Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer Arix Bioscience PLC (ARIX) Artios initiates Phase 2 study

New yorkUnited statesUnited kingdomCity ofIbrahim khalilTimothy yapSarah macleodArix bioscienceArtios pharmaNiall martinNature communicationsSarah cannon research institute at tennessee oncologyArtios pressArtios pharma limitedMerck kgaCrick institute